home / compounds / 5-Amino-1MQ
5-Amino-1MQ
Small-molecule NNMT inhibitor, not a peptide. Preclinical only.
What it is
Despite being marketed alongside peptides, this is a small molecule that inhibits the enzyme nicotinamide N-methyltransferase (NNMT).
What it does
NNMT inhibition has been associated with changes in fat cell metabolism in laboratory models.
Does it work?
Evidence is preclinical. We are not aware of controlled human trials supporting the fat-loss claims made for it commercially.
Claims vs data
Each marketing claim, tagged by what the evidence actually supports.
| Is a peptide | overreach |
| Shrinks fat cells | animal data only |
| Produces fat loss in humans | weak evidence |
Reference figures
Quoted from published reference material. These are not Peptuity recommendations.
The evidence, counted
Live counts from Europe PMC and ClinicalTrials.gov.
9 publications indexed, 0 registered interventional studies, no randomised controlled trials indexed. Evidence is minimal.
query: "5-Amino-1MQ" · checked 2026-08-07
Most-cited literature
-
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, H · Biochem Pharmacol 2018 · 75 citations
-
Chromatin and Cancer: Implications of Disrupted Chromatin Organization in Tumorigenesis and Its Diversification
Sehgal P, Chaturvedi P. · Cancers (Basel) 2023 · 26 citations
-
Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy
Li XY, Pi YN, Chen Y, Zhu Q, Xia BR. · Front Oncol 2022 · 24 citations
-
Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome
Sun WD, Zhu XJ, Li JJ, Mei YZ, Li WS, Li JH. · Front Pharmacol 2024 · 14 citations
Regulatory status
Formal, dated regulatory actions.
WADA — Prohibited List 2026
Prohibited in sport — WADA S0 (substance without any health-authority approval)
Common questions
Is 5-Amino-1MQ actually a peptide?
No. It is a small molecule that inhibits the enzyme NNMT. It is marketed alongside peptides but is chemically unrelated.
What is the evidence for fat loss?
Preclinical. NNMT inhibition changed fat-cell metabolism in laboratory models; we are not aware of controlled human trials supporting the commercial claims.
Why is it sold as capsules more than vials?
As a small molecule it is orally available, unlike most peptides, which digestion destroys. That is a chemistry difference, not an evidence advantage.
Related compounds
MOTS-c
Mitochondrial-derived peptide. Interesting biology, minimal human data.
NAD+
A coenzyme, not a peptide. Precursors have better human data than NAD+ itself.
Triple Threat blend
NAD+, MOTS-c and 5-Amino-1MQ combined. Three unproven items in one vial.
L-Carnitine
A well-studied nutrient compound, not a peptide.